The NPs were co-loaded with paclitaxel (PTX), chloroquine (CQ), CpG oligodeoxynucleotides, ovalbumin (OVA), and Atezolizumab (ATZ, an anti-PD-L1 antibody) to enhance tumor targeting and immune activation. Here, CD274 is linked to neoplasm.